1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Is Dexcom Piecing Together An Artificial Pancreas Puzzle With TypeZero?

 
• By Tina Tan

The leader in continuous glucose monitoring, Dexcom has acquired TypeZero Technologies, a specialist in developing algorithms for artificial pancreas systems. Does Dexcom have its sights on expanding beyond glucose monitoring and into insulin delivery, and building an artificial pancreas of its own?

Diabetes

Dexcom Inc. has gained a new diabetes management platform with the acquisition of TypeZero Technologies, a developer of algorithms that orchestrate insulin dosing with blood glucose monitoring data in an artificial pancreas (AP) system. Terms of the acquisition were not disclosed.

TypeZero's InControl platform emerged from the labs of the University of Virginia's Center for Diabetes Technology. It features a smartphone...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

Hundreds Of Adverse Events, Multiple Deaths, Associated With Abbott Correction Of Libre 3 Sensors

 
• By Brian Bossetta

Abbott has initiated a medical device correction for about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the US after internal testing detected a risk the device may produce inaccurate glucose readings.

Digital Health Roundup: BCIs Surge Ahead, Oura Eyes BP Clearance, AI Faces New Scrutiny

 
• By Marion Webb, Brian Bossetta, Elizabeth Orr, and Shubham Singh

Brain-computer interfaces advance toward trials and commercialization, Oura pushes for FDA-cleared blood pressure monitoring, and regulators weigh AI’s expanding role in mental health and diagnostics amid rising safety concerns.

Tandem Gears Up For Mobi Tubeless Launch In 2026 After ‘Year Of Transformation’

 
• By Marion Webb

Tandem Diabetes Care is positioning for growth in 2026 with the launch of its Mobi Tubeless pump following FDA clearance of its Android-compatible Mobi app while navigating multiple recalls during what CEO John Sheridan called a transformative year.

Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test

 
• By Marion Webb

Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.

More from Device Area

LDTs Aimed At Catching Cancers Early Hold Promise In Reducing Late-Stage Diagnoses, Study Shows

 
• By Brian Bossetta

A recent study demonstrates that certain types of blood-based tests that screen for multiple cancers at once have the potential to flip the script on cancer diagnoses, including some of the deadliest types.

Rarity Bioscience Sees Way Forward For superRCA Liquid Biopsy Platform, Despite Challenges

 
• By Barnaby Pickering

Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.

Abbott’s $21Bn Buyout Of Exact Sciences Paves Way To Fast-Growing Cancer Screening Market

 
• By Marion Webb

Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.